Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype

References

• Fang Y, Yao Q, Chen Z, Xiang J, William FE, Gibbs RA, Chen C. Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine. Med Sci Monit. 2013;19:916–26.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144:1252–61.
   PubMed Web of Science ®Google Scholar
• Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7:163–72.
   PubMed Web of Science ®Google Scholar
• Pergamo M, Miller G. Myeloid-derived suppressor cells and their role in pancreatic cancer. Cancer Gene Ther. 2017;24:100–5.
   PubMed Web of Science ®Google Scholar
• Tlsty TD, Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev. 2001;11:54–9.
   PubMed Web of Science ®Google Scholar
• van den Hooff A. Stromal involvement in malignant growth. Adv Cancer Res. 1988;50:159–96.
   PubMed Web of Science ®Google Scholar
• Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology. 2015;4:e985930.
   PubMed Web of Science ®Google Scholar
• Ohtani H. Focus on TILs. Cancer Immun. 2007;7:4.
   PubMedGoogle Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306.
   PubMed Web of Science ®Google Scholar
• Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004;28:e26–31.
   PubMed Web of Science ®Google Scholar
• Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, Castagnoli C, Migliorini P, Perconti G, Giallongo A, Milella M, et al. An integrated humoral and cellular response is elicited in pancreatic cancer by α-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer. 2009;125:639–48.
   PubMed Web of Science ®Google Scholar
• Cappello P, Principe M, Bulfamante S, Novelli F. Alpha-Enolase (ENO1), a potential target in novel immunotherapies. Front Biosci (Landmark Ed). 2017;22:944–59.
   PubMed Web of Science ®Google Scholar
• Amedei A, Niccolai E, Benagiano M, Della Bella C, Cianchi F, Bechi P, Taddei A, Bencini L, Farsi M, Cappello P, et al. Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol Immunother. 2013;62:1249–60.
   PubMed Web of Science ®Google Scholar
• Cappello P, Rolla S, Chiarle R, Principe M, Cavallo F, Perconti G, Feo S, Giovarelli M, Novelli F. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Gastroenterology. 2013;144:1098–106.
   PubMed Web of Science ®Google Scholar
• Niccolai E, Cappello P, Taddei A, Ricci F, D'Elios M, Benagiano M, Bechi P, Bencini L, Ringressi M, Coratti A, et al. Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma. Int J Oncol. 2016;49:393–401.
   PubMed Web of Science ®Google Scholar
• Chew V, Toh HC, Abastado J-P. Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol. 2012;2012:1–10.
   Google Scholar
• Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006;16:38–52.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22:231–7.
   PubMed Web of Science ®Google Scholar
• Pinton L, Solito S, Damuzzo V, Francescato S, Pozzuoli A, Berizzi A, Mocellin S, Rossi CR, Bronte V, Mandruzzato S, et al. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. Oncotarget. 2016;7:1168–84.
   PubMed Web of Science ®Google Scholar
• Seo YD, Pillarisetty VG. T-cell programming in pancreatic adenocarcinoma: a review. Cancer Gene Ther. 2017;24:106–13.
   PubMed Web of Science ®Google Scholar
• De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011;208:469–78.
   PubMed Web of Science ®Google Scholar
• Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21:381–95.
   PubMed Web of Science ®Google Scholar
• Barth TK, Imhof A. Fast signals and slow marks: the dynamics of histone modifications. Trends Biochem Sci. 2010;35:618–26.
   PubMed Web of Science ®Google Scholar
• Hu M, Yao J, Cai L, Bachman KE, van den Brûle F, Velculescu V, Polyak K. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet. 2005;37:899–905.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Canales J, Hanson JC, Tangrea MA, Erickson HS, Albert PS, Wallis BS, Richardson AM, Pinto PA, Linehan WM, Gillespie JW, et al. Identification of a unique epigenetic sub-microenvironment in prostate cancer. J Pathol. 2007;211:410–9.
   PubMed Web of Science ®Google Scholar
• Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM, Woodson KG. Gene promoter methylation in prostate tumor-associated stromal cells. JNCI J Natl Cancer Inst. 2006;98:255–61.
   Web of Science ®Google Scholar
• Dey P. Epigenetics meets the tumor microenvironment. Med Epigenetics. 2013;1:31–6.
   Google Scholar
• Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23:249–62.
   PubMed Web of Science ®Google Scholar
• Sinder BP, Zweifler L, Koh AJ, Michalski MN, Hofbauer LC, Aguirre JI, Roca H, McCauley LK. Bone mass is compromised by the chemotherapeutic trabectedin in association with effects on osteoblasts and macrophage efferocytosis. J Bone Miner Res. 2017;32(10):2116–2127
   PubMed Web of Science ®Google Scholar
• Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, Olimpio CO, Bonardi C, Garbi A, Lissoni A, et al. Anti-inflammatory properties of the novel Antitumor Agent Yondelis (Trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005;65:2964–71.
   PubMed Web of Science ®Google Scholar
• Rinehart KL, Holt TG, Fregeau NL, Keifer PA, Wilson GR, Perun TJ, Sakai R, Thompson AG, Stroh JG, Shield LS. Bioactive compounds from aquatic and terrestrial sources. J Nat Prod. 1990;53:771–92.
   PubMed Web of Science ®Google Scholar
• López-Guerrero JA, Romero I, Poveda A. Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer. Chin J Cancer. 2015;34:41–9.
   PubMed Web of Science ®Google Scholar
• Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C, Cupissol D, Selle F, Isambert N, Piperno-Neumann S, et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2015;16:457–64.
   PubMed Web of Science ®Google Scholar
• Simoens C, Korst AEC, De Pooter CMJ, Lambrechts HAJ, Pattyn GGO, Faircloth GT, Lardon F, Vermorken JB. In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects. Br J Cancer. 2003;89:2305–11.
   PubMed Web of Science ®Google Scholar
• Gajate C, An F, Mollinedo F. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells: Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J Biol Chem. 2002;277:41580–9.
   PubMed Web of Science ®Google Scholar
• Larsen AK, Galmarini CM, D'Incalci M. Unique features of trabectedin mechanism of action. Cancer Chemother Pharmacol. 2016;77:663–71.
   PubMed Web of Science ®Google Scholar
• D'Incalci M, Badri N, Galmarini CM, Allavena P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer. 2014;111:646–50.
   PubMed Web of Science ®Google Scholar
• Miao X, Koch G, Straubinger RM, Jusko WJ. Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells. Cancer Chemother Pharmacol. 2016;77:181–93.
   PubMed Web of Science ®Google Scholar
• Miao X, Koch G, Ait-Oudhia S, Straubinger RM, Jusko WJ. Pharmacodynamic modeling of cell cycle effects for gemcitabine and trabectedin combinations in pancreatic cancer cells. Front Pharmacol. 2016;7:421.
   PubMed Web of Science ®Google Scholar
• D'Incalci M, Zambelli A. Trabectedin for the treatment of breast cancer. Expert Opin Investig Drugs. 2016;25:105–15.
   PubMed Web of Science ®Google Scholar
• Liguori M, Buracchi C, Pasqualini F, Bergomas F, Pesce S, Sironi M, Grizzi F, Mantovani A, Belgiovine C, Allavena P. Functional TRAIL receptors in monocytes and tumor-associated macrophages: a possible targeting pathway in the tumor microenvironment. Oncotarget. 2016;7:41662–76.
   PubMed Web of Science ®Google Scholar
• Italiani P, Boraschi D. From monocytes to M1/M2 macrophages: Phenotypical vs. functional differentiation. Front Immunol. 2014;5:514.
   PubMed Web of Science ®Google Scholar
• Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000;100:655–69.
   PubMed Web of Science ®Google Scholar
• Takemoto N, Intlekofer AM, Northrup JT, Wherry EJ, Reiner SL. Cutting edge: IL-12 inversely regulates T-bet and Eomesodermin expression during pathogen-induced CD8+ T cell differentiation. J Immunol. 2006;177:7515–9.
   PubMed Web of Science ®Google Scholar
• Bally APR, Lu P, Tang Y, Austin JW, Scharer CD, Ahmed R, Boss JM. NF-κB regulates PD-1 expression in macrophages. J Immunol. 2015;194:4545–54.
   PubMed Web of Science ®Google Scholar
• Homey B, Alenius H, Müller A, Soto H, Bowman EP, Yuan W, McEvoy L, Lauerma AI, Assmann T, Bünemann E, et al. CCL27–CCR10 interactions regulate T cell–mediated skin inflammation. Nat Med. 2002;8:157–65.
   PubMed Web of Science ®Google Scholar
• De Filippo K, Dudeck A, Hasenberg M, Nye E, van Rooijen N, Hartmann K, Gunzer M, Roers A, Hogg N. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood. 2013;121:4930–7.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–22.
   PubMed Web of Science ®Google Scholar
• Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49–61.
   PubMed Web of Science ®Google Scholar
• Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254–65.
   PubMed Web of Science ®Google Scholar
• Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 2012;21:822–35.
   PubMed Web of Science ®Google Scholar
• Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut. 2014;63:1769–81.
   PubMed Web of Science ®Google Scholar
• Shen K-Y, Song Y-C, Chen I-H, Chong P, Liu S-J. Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide. Hum Vaccin Immunother. 2014;10:3241–50.
   PubMed Web of Science ®Google Scholar
• Bader JE, Enos RT, Velazquez KT, Carson MS, Nagarkatti M, Nagarkatti PS, Chatzistamou I, Davis JM, Carson JA, Robinson C, et al. Macrophage depletion using clodronate liposomes decreases tumorigenesis and alters gut microbiota in the AOM/DSS mouse model of colon cancer. Am J Physiol - Gastrointest Liver Physiol. 2017 Oct 12:ajpgi.00229.2017. doi: 10.1152/ajpgi.00229.2017. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Williams CB, Yeh ES, Soloff AC. Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer. 2016;2:15025.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and Its Ligands in Tolerance and Immunity. Annu Rev Immunol. 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, et al. T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition. Science. 2017;355:1428–1433.
   PubMed Web of Science ®Google Scholar
• Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT, Daugherty CZ, Koenig L, Yu K, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355:1423–7.
   PubMed Web of Science ®Google Scholar
• Guo Z, Wang H, Meng F, Li J, Zhang S. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. J Transl Med. 2015;13:247.
   PubMed Web of Science ®Google Scholar
• Lomberk GA, Iovanna J, Urrutia R. The promise of epigenomic therapeutics in pancreatic cancer. Epigenomics. 2016;8:831–42.
   PubMed Web of Science ®Google Scholar
• Blasco F, Peñuelas S, Cascalló M, Hernández JL, Alemany C, Masa M, Calbó J, Soler M, Nicolás M, Pérez-Torras S, et al. Expression profiles of a human pancreatic cancer cell line upon induction of apoptosis search for modulators in cancer therapy. Oncology. 2004;67:277–90.
   PubMed Web of Science ®Google Scholar
• Avan A, Crea F, Paolicchi E, Funel N, Galvani E, Marquez VE, Honeywell RJ, Danesi R, Peters GJ, Giovannetti E. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-Deazaneplanocin a with gemcitabine in pancreatic cancer cells. Mol Cancer Ther. 2012;11:1735–46.
   PubMed Web of Science ®Google Scholar
• Chen N-M, Neesse A, Dyck ML, Steuber B, Koenig AO, Lubeseder-Martellato C, Winter T, Forster T, Bohnenberger H, Kitz J, et al. Context-dependent epigenetic regulation of nuclear factor of activated T Cells 1 in pancreatic plasticity. Gastroenterology. 2017;152:1507–1520. e15.
   PubMed Web of Science ®Google Scholar
• Mishra VK, Wegwitz F, Kosinsky RL, Sen M, Baumgartner R, Wulff T, Siveke JT, Schildhaus H-U, Najafova Z, Kari V, et al. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. Nucleic Acids Res 2017;45(11):6334–6349
   PubMed Web of Science ®Google Scholar
• Dahl JA, Collas P. A rapid micro chromatin immunoprecipitation assay (ChIP). Nat Protoc. 2008;3:1032–45.
   PubMed Web of Science ®Google Scholar